RICHARD A contact VAN ETTEN

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. pmc Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop
    Richard A Van Etten
    Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
    Leuk Lymphoma 54:1151-8. 2013
  2. pmc The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues
    Richard A Van Etten
    Division of Hematology Oncology, Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
    Haematologica 96:590-601. 2011
  3. ncbi request reprint BCL6: a novel target for therapy of Ph+ B cell acute lymphoblastic leukemia
    Richard A Van Etten
    Molecular Oncology Research Institute, Division of Hematology Oncology, Tufts Medical Center, Boston, MA 02111, USA
    Cancer Cell 20:3-5. 2011

Research Grants

  1. REGULATION AND FUNCTION OF C AB1 NUCLEAR TYROSINE KINASE
    RICHARD VAN ETTEN; Fiscal Year: 2001
  2. INHIBITOR OF THE C ABL TYROSINE KINASE
    RICHARD VAN ETTEN; Fiscal Year: 2002
  3. Pathogenesis & Therapy of 8p11 Leukemia/Lymphoma
    RICHARD VAN ETTEN; Fiscal Year: 2008
  4. Novel Cellular Therapies for Ph+ leukemia
    RICHARD A contact VAN ETTEN; Fiscal Year: 2010

Detail Information

Publications3

  1. pmc Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop
    Richard A Van Etten
    Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
    Leuk Lymphoma 54:1151-8. 2013
    ..A report summarizing the pertinent advances in MPN has been published separately...
  2. pmc The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues
    Richard A Van Etten
    Division of Hematology Oncology, Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
    Haematologica 96:590-601. 2011
    ..Finally, the clinical role of the new JAK2- and BCR-ABL1-inhibitors is considered. Much further progress is likely in several of these areas soon...
  3. ncbi request reprint BCL6: a novel target for therapy of Ph+ B cell acute lymphoblastic leukemia
    Richard A Van Etten
    Molecular Oncology Research Institute, Division of Hematology Oncology, Tufts Medical Center, Boston, MA 02111, USA
    Cancer Cell 20:3-5. 2011
    ..In a recent issue of Nature, Duy et al. describe a novel role for BCL6 at the center of a transcriptional network in Ph(+) acute lymphoblastic leukemia cells that modulates their leukemogenicity and response to kinase inhibitors...

Research Grants4

  1. REGULATION AND FUNCTION OF C AB1 NUCLEAR TYROSINE KINASE
    RICHARD VAN ETTEN; Fiscal Year: 2001
    ..Finally, primary abl-/- fibroblasts (before and after rescue with selected abl constructs) will be used to assess the role of c-abl in growth arrest induced by DNA damage. ..
  2. INHIBITOR OF THE C ABL TYROSINE KINASE
    RICHARD VAN ETTEN; Fiscal Year: 2002
    ..These experiments will yield important new information about the function and regulation of c-Abl and the mode of activation of leukemogenic forms of Abl, and identify new avenues for anti-leukemic therapies. ..
  3. Pathogenesis & Therapy of 8p11 Leukemia/Lymphoma
    RICHARD VAN ETTEN; Fiscal Year: 2008
    ..abstract_text> ..
  4. Novel Cellular Therapies for Ph+ leukemia
    RICHARD A contact VAN ETTEN; Fiscal Year: 2010
    ..PHS 398/2590 (Rev. 11/07) Page 2 Continuation Format Page Program Director/Principal Investigator (Last, First, Middle): Van Etten R.A./Klingemann H.K. ..